ImmunOs Therapeutics´ team has extensive expertise in the field of drug development and global commercialization in immunology, immunotherapy, and oncology.
The Company´s mission is to develop the next generation of novel immunotherapeutics that will improve the lives of patients with serious diseases.
CHIEF EXECUTIVE OFFICER
Sean R. Smith has been CEO and a member of the Board of Directors for ImmunOs Therapeutics AG since May of 2017. He previously spent over 15 years at MSD/Merck and Co., Inc in positions of increasing responsibility in commercial leadership, cross-departmental management, business development, country and regional operations with broad exposure to multiple therapeutic areas including early-stage clinical, in-line, and launch portfolios in hospital / specialty, infectious disease, general medicine, and vaccines. He has extensive leadership experience in global markets focused on North America, Europe, Asia-Pacific, China, Japan, and Latin America. Sean received his B.S. from Pennsylvania State University and M.B.A. from the University of Denver.
CHIEF OPERATING OFFICER &
CHIEF BUSINESS OFFICER
Jeff Abbey has been Chief Operating Officer and Chief Business Officer of ImmunOs since August 2021. Jeff brings over twenty years of expertise in the development of innovative biopharmaceutical products and has a strong track record in business development and capital markets transactions in the U.S. and Europe, including private and public placements, in- and out-licensing, and joint ventures. Jeff spent over 16 years at Argos Therapeutics, Durham, NC, USA, serving as CEO for over eight years and, prior to that, as VP and Business Development. He led Argos through completion of a phase 3 trial, raised over $250 million in equity financings, including an IPO on NASDAQ, and completed numerous partnering transactions with international biopharmaceutical companies. Jeff received a bachelor’s degree from Brown University and an MBA and JD from the University of Virginia.
CHIEF SCIENTIFIC OFFICER &
Dr. Osiris Marroquin Belaunzaran brings over 15 years of research expertise in the fields of immuno-oncology and autoimmunity. He earned his Ph.D. in Bioengineering and Biotechnology from the Swiss Federal Institute of Technology (EPFL) in Lausanne. As a founding member of the executive leadership team, he played the leading role in company creation and business development, including raising equity capital. Osiris is an inventor of several granted patents and continues to lead scientific innovation at ImmunOs R&D facilities. His expertise covers multiple areas of research including drug discovery, protein engineering, antibody development, immunology, drug delivery systems, and pre-clinical work.
CHIEF MEDICAL OFFICER & CO-FOUNDER
Prof. Dr. Christoph Renner is a Professor of Medical Oncology at the University of Basel. Previous appointments include Head of the Department of Internal Medicine and Oncology, Head of the Cancer Center, Head of the division of Clinical Immunology and Professor for Clinical and Experimental Oncology at the University of Zurich. Christoph joined the Swiss Tumor Institute in January 2013 and started a Cancer Center Initiative Network. He has a strong background in antibody engineering and has been an affiliate of the Ludwig Institute for Cancer Research for more than 15 years and a senior physician specialist in oncology, onco-immunology and internal medicine at Hirslanden Hospital Zurich. Prof. Dr. Renner is a member of different research organizations and has served on the board of the Swiss Group for Clinical Cancer Research for six years. He is currently consulting four biotech companies as a scientific advisor, with one being listed on NASDAQ stock exchange.
SENIOR VICE PRESIDENT CLINICAL DEVELOPMENT
Claudia Berger is a proven expert in the field of clinical development and has been focusing on clinical trial operations and project management for more than 15 years. Before joining ImmunOs Therapeutics, she served as Director Clinical Operations at Inflazome Ltd, an Irish company recently acquired by Roche. Prior to that, she headed clinical operations at several biopharmaceutical companies such as Kinarus AG and Delenex Therapeutics, leading Phase I/II clinical programs, including profiling, biomarker and proof-of-concept studies with both biologics and small molecules and establishing quality assurance systems. From 2007 to 2012, she held several positions of increasing responsibility at the Novartis Institute for Biomedical Research (NIBR), most recently as Principal Clinical Scientist. Claudia Berger holds a Master of Science Degree in Pharmacy and a Diploma as a University Professional of Advanced Studies in Pharmaceutical Medicine.
HEAD OF NON-CLINICAL DEVELOPMENT
Dr. Darryl H. Patrick is a pharmaceutical research and development executive specializing in non-clinical development for over 30 years. He was Vice President, Exploratory Development at Vertex Pharmaceuticals and responsible for all non-clinical development activities and clinical pharmacology directing programs through to proof-of-concept. While at Vertex, he was a member of the management team and responsible for the first NCE developed within the Company. Darryl began his career at Merck/MSD Research Laboratories, working in numerous roles over 20 years and ultimately serving as Vice President/Head, Worldwide Safety Assessment. In this function, he was responsible for all non-clinical aspects of potential drug development candidates, including toxicologic evaluation, definition of pre-clinical drug development candidate plans, interaction with drug development teams, and preparation of regulatory submissions including INDs/NDAs.
HEAD OF PRODUCT DEVELOPMENT
Dr. Lorenz Vogt has been a pharmaceutical research and development executive for more than 20 years. He is specialized in technical development and CMC of biologics, including antibodies, proteins, DNA & RNA containing virus-like particles, glycoproteins, peptides, and combination products in immunology, dermatology, bone grafting, and therapeutic & prophylactic vaccines. He was responsible in different biotech companies for managing multidisciplinary projects, technical development activities, CMC, preparation of regulatory submissions including IMPD/IND, QA and establishing pharmaceutical quality systems for acquiring Swiss medic licenses. Lorenz began his career at Cytos Biotechnology AG, working in various roles for 10 years and ultimately serving as Head of Bioprocess Development and Production. Lorenz holds a Ph.D. in Developmental Neurobiology, a Master in Biochemistry and Molecular Biology, and a Master of Advanced Studies in Business Administration.